United Therapeutics' Ralinepag Meets Primary Endpoint in PAH Study
United Therapeutics announced that its drug ralinepag successfully met its primary endpoint in a study for pulmonary arterial hypertension (PAH).
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)Sources
United Therapeutics Announces Advance Outcomes Study Of Ralinepag - TradingView
United Therapeutics Announces Advance Outcomes Study Of Ralinepag TradingView
Read full article →United Therapeutics' ralinepag meets primary endpoint in PAH study
Read full article →Coverage Timeline
Related Stories

Oldest Plague Outbreak Discovered in Siberia, Dating Back 5,500 Years
just now

Extreme Training: What Heat Training Does to the Body
just now

Flood victims in Accra to receive free NHIS registration as health authorities warn of disease risk
16m ago

Hospitals in South Moravian Region Lack Air Conditioning, Causing Patient Discomfort
22m ago